general 1. acutely ill 72 hours prior to or at screening. participants meeting this criterion may be rescheduled within the relevant window periods. participants with minor illnesses can be enrolled at the discretion of the investigator. 2. history of angioedema or anaphylaxis. vaccines and other injections 3. prior receipt of a sars-cov-2 vaccine. 4. history of severe allergic reaction to any ingredient of this vaccine (lipids (sm-102, polyethylene glycol \[peg\] 2000 dimyristoyl glycerol \[dmg\], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine \[dspc\]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose). 5. live attenuated vaccines received within 30 days before first vaccination (eg, measles, mumps, and rubella \[mmr\]; oral polio vaccine \[opv\]; varicella; yellow fever; live attenuated influenza vaccine, live attenuated zoster vaccine). 6. any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (eg, tetanus, human papilloma virus (hpv), pneumococcal, hepatitis a or b). 7. blood products, systemic immunoglobulins, or monoclonal antibodies (including against sars-cov-2) received within 90 days before first vaccination.

general 1. acutely ill 72 hours prior to or at screening. participants meeting this criterion may be rescheduled within the relevant window periods. participants with minor illnesses can be enrolled at the discretion of the investigator. 2. history of angioedema or anaphylaxis. vaccines and other injections 3. prior receipt of a sars-cov-2 vaccine. 4. history of severe allergic reaction to any ingredient of this vaccine (lipids (sm-102, polyethylene glycol \[peg\] 2000 dimyristoyl glycerol \[dmg\], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine \[dspc\]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose). 5. live attenuated vaccines received within 30 days before first vaccination (eg, measles, mumps, and rubella \[mmr\]; oral polio vaccine \[opv\]; varicella; yellow fever; live attenuated influenza vaccine, live attenuated zoster vaccine). 6. any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (eg, tetanus, human papilloma virus (hpv), pneumococcal, hepatitis a or b). 7. blood products, systemic immunoglobulins, or monoclonal antibodies (including against sars-cov-2) received within 90 days before first vaccination.

general acutely ill 72 hours prior to or at screening. participants meeting this criterion may be rescheduled within the relevant window periods. participants with minor illnesses can be enrolled at the discretion of the investigator. history of angioedema or anaphylaxis. vaccines and other injections prior receipt of a sars-cov-2 vaccine. history of severe allergic reaction to any ingredient of this vaccine (lipids (sm-102, polyethylene glycol [peg] 2000 dimyristoyl glycerol [dmg], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [dspc]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose). live attenuated vaccines received within 30 days before first vaccination (eg, measles, mumps, and rubella [mmr]; oral polio vaccine [opv]; varicella; yellow fever; live attenuated influenza vaccine, live attenuated zoster vaccine). any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (eg, tetanus, human papilloma virus (hpv), pneumococcal, hepatitis a or b). blood products, systemic immunoglobulins, or monoclonal antibodies (including against sars-cov-2) received within 90 days before first vaccination.

general acutely ill 72 hours prior to or at screening. participants meeting this criterion may be rescheduled within the relevant window periods. participants with minor illnesses can be enrolled at the discretion of the investigator. history of angioedema or anaphylaxis. vaccines and other injections prior receipt of a sars-cov-2 vaccine. history of severe allergic reaction to any ingredient of this vaccine (lipids (sm-102, polyethylene glycol [peg] 2000 dimyristoyl glycerol [dmg], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [dspc]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose). live attenuated vaccines received within 30 days before first vaccination (eg, measles, mumps, and rubella [mmr]; oral polio vaccine [opv]; varicella; yellow fever; live attenuated influenza vaccine, live attenuated zoster vaccine). any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (eg, tetanus, human papilloma virus (hpv), pneumococcal, hepatitis a or b). blood products, systemic immunoglobulins, or monoclonal antibodies (including against sars-cov-2) received within 90 days before first vaccination.

general acutely ill 72 hours prior to or at screening. volunteers meeting this criterion may be rescheduled within the relevant window periods. participants with minor illnesses can be enrolled at the discretion of the investigator. history of angioedema or anaphylaxis. self-reported previous covid-19 diagnosis. vaccines and other injections prior receipt of a sars-cov-2 vaccine. history of severe allergic reaction to any ingredient of this vaccine (lipids (sm-102, polyethylene glycol [peg] 2000 dimyristoyl glycerol [dmg], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [dspc]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose). live attenuated vaccines received within 30 days before first vaccination (eg, measles, mumps, and rubella [mmr]; oral polio vaccine [opv]; varicella; yellow fever; live attenuated influenza vaccine, live attenuated zoster vaccine). any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (eg, tetanus, human papilloma virus (hpv), pneumococcal, hepatitis a or b). blood products, systemic immunoglobulins, or monoclonal antibodies (including against sars-cov-2) received within 90 days before first vaccination.

general acutely ill 72 hours prior to or at screening. volunteers meeting this criterion may be rescheduled within the relevant window periods. participants with minor illnesses can be enrolled at the discretion of the investigator. history of angioedema or anaphylaxis. self-reported previous covid-19 diagnosis. vaccines and other injections prior receipt of a sars-cov-2 vaccine. history of severe allergic reaction to any ingredient of this vaccine (lipids (sm-102, polyethylene glycol [peg] 2000 dimyristoyl glycerol [dmg], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [dspc]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose). live attenuated vaccines received within 30 days before first vaccination (eg, measles, mumps, and rubella [mmr]; oral polio vaccine [opv]; varicella; yellow fever; live attenuated influenza vaccine, live attenuated zoster vaccine). any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (eg, tetanus, human papilloma virus (hpv), pneumococcal, hepatitis a or b). blood products, systemic immunoglobulins, or monoclonal antibodies (including against sars-cov-2) received within 90 days before first vaccination.